Related Experiment Video
Updated: Oct 26, 2025

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
Published on: August 9, 2012
Effects of β3-adrenoceptor agonist on acute urinary retention in a rat model
Tae Il Noh1, Ji Sung Shim1, Sung Gu Kang1
1Department of Urology, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul, 02841, Korea.
Purpose:
To investigate the protective effect of mirabegron on bladder dysfunction in an acute urinary retention rat model.
Materials And Methods:
Thirty-six 16-week Sprague-Dawley rats were assigned to the mirabegron and normal saline (N/S) groups. Each group of eighteen was divided into sub-groups of 6 for 30 min, 2 h, and 24 h. They were administered mirabegron (10 mg/kg) and N/S daily for 4 weeks, respectively. Mirabegron and N/S groups were divided into sub-groups of 6 rats for 30 min, 2 h, and 24 h. The changes in bladder blood flow were measured using laser Doppler (moorVMS-LDF2). Histopathological examination of the bladder and nitric oxide (NO) measurement were performed.
Result:
During the urinary retention phase in the mirabegron group, it showed higher and rapider recovery of blood flow; the lowest at 19.5% ± 3.68% at 3 min, a significant recovery from the lowest value as 23.7 ± 3.4% at 10 min, than that in the N/S group; 15.1 ± 1.84% at 5 min, 23.7 ± 3.4% at 20 min, respectively (P < 0.05). At 30 min, 120 min, and 24 h after reperfusion, the recovery of blood flow in the mirabegron group was significantly higher than that in the N/S group (mirabegron: 41.1 ± 1.7%, 59.9 ± 7.2%, and 89.7 ± 4.4%, N/S: 31.3 ± 2.1%, 47.3 ± 4.5%, 83.9 ± 3.6%, respectively (P < 0.05)). NO levels tended to be higher in the mirabegron group; however, the difference was not statistically significant. Histological examination revealed that the mirabegron group showed recovery close to normal tissue after 24 h.
Conclusions:
In an acute urinary retention rat model, mirabegron maintained and restored higher bladder blood flow, resulting in protective and recovery effect after acute urinary retention.
Insights
Mirabegron demonstrated a protective effect in rats with acute urinary retention by improving bladder blood flow recovery. This treatment aided in restoring bladder tissue function following urinary retention.
Area of Science:
- Urology
- Pharmacology
- Physiology
Background:
- Acute urinary retention (AUR) can lead to bladder dysfunction.
- Understanding the mechanisms and potential treatments for bladder protection during AUR is crucial.
Purpose of the Study:
- To investigate the protective effects of mirabegron on bladder dysfunction in an acute urinary retention rat model.
- To assess mirabegron's impact on bladder blood flow, nitric oxide levels, and tissue histology.
Main Methods:
- Thirty-six rats were divided into mirabegron and normal saline (N/S) groups.
- Bladder blood flow was measured using laser Doppler, and nitric oxide (NO) levels were assessed.
- Histopathological examination of bladder tissue was performed at 30 minutes, 2 hours, and 24 hours.
Main Results:
- Mirabegron significantly enhanced and accelerated bladder blood flow recovery compared to N/S.
- NO levels were higher in the mirabegron group, though not statistically significant.
- Histological analysis showed near-normal bladder tissue in the mirabegron group after 24 hours.
Conclusions:
- Mirabegron demonstrates a protective and restorative effect in an acute urinary retention rat model.
- The drug helps maintain and restore bladder blood flow, mitigating dysfunction.
- These findings suggest mirabegron's potential therapeutic value in managing conditions associated with acute urinary retention.
More Related Videos
11:46Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
Published on: April 27, 2014
10:07Cystometric and External Urethral Sphincter Measurements in Awake Rats with Implanted Catheter and Electrodes Allowing for Repeated Measurements
Published on: January 30, 2018
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Antihypertensive Drugs: Action of β1 Blockers
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...